GlassScriptPhysician profile
Kayvan Kamali
NPI 1013912856
$35,323.92
in general payments reported to CMS, 2019-2025
37 companies · $5,288 in 2025
The $5,288 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,279 · 2020: $2,758 · 2021: $5,201 · 2022: $5,222 · 2023: $6,835 · 2024: $4,741 · 2025: $5,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,863.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,032.41 | 2019-2025 | |
| Amgen INC. | $6,896.05 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Lilly USA, LLC | $2,022.76 | 2019-2025 | Taltz |
| Ucb, INC. | $1,871.13 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,514.50 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,357.94 | 2019-2025 | Tremfya, Simponi Aria |
| Radius Health, INC. | $1,190.70 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $1,127.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,115.36 | 2021-2025 | Saphnelo |
| Pfizer INC. | $1,108.48 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $1,070.94 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $882.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $498.99 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $324.27 | 2023-2025 | Idacio |
| Mallinckrodt Hospital Products INC. | $312.07 | 2021-2025 | Acthar |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $257.93 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $225.36 | 2023-2025 | Belbuca, Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.30 | 2019-2024 | |
| Celgene Corporation | $191.74 | 2019 | |
| Genentech USA, INC. | $153.37 | 2019-2025 | Gazyva |
| Eisai INC. | $141.74 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Bioventus LLC | $103.34 | 2022-2023 | Durolane |
| Alexion Pharmaceuticals, INC. | $92.26 | 2021-2024 | Strensiq |
| Organon LLC | $85.54 | 2023-2025 | Hadlima, Renflexis |
| Sandoz INC. | $71.99 | 2023 | Hyrimoz |
| Biodelivery Sciences International, INC. | $61.30 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $49.00 | 2023-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $44.01 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.05 | 2019 | |
| Forte Bio-Pharma LLC | $28.23 | 2024 | Prolate, Nalocet |
| Shield Therapeutics INC | $24.53 | 2025 | |
| Assertio Therapeutics, INC. | $18.67 | 2019 | |
| Pacira Therapeutics, INC. | $17.42 | 2019 | |
| Mylan Institutional INC. | $16.51 | 2023 | |
| Tonix Medicines, INC. | $14.97 | 2025 | Tonmya |
| Orthogenrx INC. | $14.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayvan Kamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.